器官晶片新創久浪智醫完成2億元A輪，老股東全數跟投
Meet創業小聚 · 2026-10-19
2024年成立的久浪智醫以AI結合器官晶片加速藥物驗證，完成2億元（約600萬美元）A輪，既有投資人全數參與，資金將用於擴充實驗設施與海外布局。其吸入式肺部晶片入選美國FNIH試點計畫，已服務逾30家客戶並設立美國子公司。
Organ-on-chip startup Anivance AI closes NT$200 million Series A with all existing investors following on
Anivance AI, founded in 2024 to speed drug testing with AI and organ-on-chip models, has raised a NT$200 million (about US$6 million) Series A in which every existing investor took part. Funds go to lab infrastructure and overseas expansion; its inhalation lung-chip was picked for a US FNIH pilot, and it has over 30 clients and a US subsidiary.